Wexford Capital’s Chembio diagnostics, Inc. CEMI Stock Holding History

Wexford Capital’s Portfolio CEMI Stock Details CEMI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-100,000	Closed	-$609K	–	173
2019 Q2	$609K	Hold	100,000	–	–	0.07%	101
2019 Q1	$555K	Hold	100,000	–	–	0.05%	78
2018 Q4	$566K	Buy	+100,000	New	+$737K	0.05%	65

Other funds holding CEMI

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

SAM

Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

SBH

Segall Bryant & Hamill Chicago, Illinois $6.98B AUM 34.78% 1-Year Est. Return

AIP

ARS Investment Partners New York $2.29B AUM 113.95% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Roubaix Capital Denver, Colorado $214M AUM 32.43% 1-Year Est. Return

Wexford Capital's CEMI Position: Q3 2019 in Review

Wexford Capital sold out of Chembio diagnostics, Inc. (CEMI) in Q3 2019, closing a stake of 100,000 shares — an estimated $609K sold.

Wexford Capital first reported a position in CEMI in Q4 2018 and held it in 3 quarters. The position peaked at $609K in Q2 2019. 45 funds tracked by Wall St. Rank hold CEMI as of Q3 2019.

Wexford Capital reported no remaining Chembio diagnostics, Inc. position as of Q3 2019 after selling out during the quarter.
Wexford Capital sold 100,000 Chembio diagnostics, Inc. shares in Q3 2019, an estimated $609K.
Wexford Capital first reported a position in Chembio diagnostics, Inc. in Q4 2018 and held it in 3 quarters.
Wexford Capital's Chembio diagnostics, Inc. position peaked at $609K in Q2 2019.
45 funds tracked by Wall St. Rank held Chembio diagnostics, Inc. as of Q3 2019.

Based on Wexford Capital's 13F filing for Q3 2019, filed 14 Nov 2019.